Accretion Nutraveda IPO: GMP & Share Price

Accretion Nutraveda IPO 2026 GMP, Share Price

Accretion Nutraveda Ltd. has launched its Initial Public Offering (IPO), marking a key milestone for the Ahmedabad-based Ayurvedic and nutraceutical manufacturer. The issue has attracted attention from SME IPO investors due to its niche business model in the wellness segment.

IPO Timeline & Key Dates

Event	Date
IPO Open	January 27, 2026
IPO Close	January 30, 2026
Basis of Allotment	February 2, 2026
Refunds Initiated	February 3, 2026
Shares Credited to Demat	February 3, 2026
Listing on BSE SME	February 4, 2026

Price Band & Issue Size

• Price Band: ₹122 – ₹129 per share
• Lot Size: 1,000 shares
• Total Issue Size: ~₹24.77 crore (19.20 lakh shares)
• Listing Exchange: BSE SME segment

What This Means

To apply, an investor must bid for at least 2 lots (2,000 shares) which equals a minimum investment of ~₹2.58 lakh at the upper price band.

About Accretion Nutraveda

Accretion Nutraveda is a Contract Development and Manufacturing Organization (CDMO) specializing in Ayurvedic and nutraceutical products. The company produces tablets, capsules, liquids, powders, oils, balms, creams, and gels. Its product range targets areas like:

• Bone and joint health
• Liver care
• Women’s health
• Respiratory wellness
• Cognitive support

The firm markets products both domestically and internationally (e.g., Sri Lanka, Singapore, USA).

Financial Details

Latest financial figures show rapid revenue growth over the past few years (FY2023–FY2025), with profitability improving alongside scale.

Example: Revenue jumped from around ₹2.90 crore in FY2023 to ₹16 crore in FY2025.

GMP (Grey Market Premium) Status

GMP represents the unofficial price at which IPO shares are trading in the grey market before listing, indicating expected listing gains.

As of the latest available data:

• Accretion Nutraveda IPO GMP is not yet showing any premium (₹0). This suggests that in the unofficial grey market, there has been no active premium reported so far.

What This Implies

• A GMP of ₹0 means initial grey market sentiment is neutral.
• Often, GMP trends pick up closer to the listing date when subscription figures are known.
• GMP is not guaranteed and can change rapidly—sometimes significantly—based on investor interest. It’s mainly a sentiment indicator, not a definitive price predictor.

Expected Listing Price & Gains

Since no reliable GMP data is available yet, expected listing price and gains remain uncertain.

• If the IPO lists at the upper price band (₹129), potential gains could be minimal initially unless demand increases near listing.
• Investors should monitor subscription trends and grey market activity closer to February 4, 2026.

Subscription Categories & Allocations

The public portion is split typically between:

• Retail Investors
• Qualified Institutional Buyers (QIBs)
• High-Net-Worth Individuals (HNIs)

Exact quotas — usually around **35% retail, 50% QIB, and 15% HNI — are standard for many SME IPOs.

Should You Apply?

Positive Factors

• Established GMP-certified manufacturing facility
• Diverse product range across health and wellness categories
• Growing nutraceutical demand in both domestic and global markets

Risk Factors

SME IPOs can be more volatile and less liquid than mainboard issues.
Listing gains are not guaranteed. GMP can shift negative or positive.
Business performance and subscription response matter most for final stock performance.

Investor Takeaway

Accretion Nutraveda IPO is a relatively small-size SME offering with potential exposure to the growing Ayurvedic/nutraceutical sector.
GMP is flat currently, suggesting cautious early sentiment—but that can change as the market digests subscription data and approaches listing day.
Investors should keep an eye on subscription numbers and GMP trends closer to listing for a clearer picture of expected performance.

Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice. Always consult a qualified financial advisor before making investment decisions.